Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03422536
Title Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Arizona
Indications

auditory system cancer

lip cancer

paranasal sinus cancer

nasopharynx carcinoma

head and neck squamous cell carcinoma

Therapies

Ficlatuzumab

Cetuximab + Ficlatuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.